{"preliminary_commentary":{"by_channel":{"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"Neo-KAN","nct_id":"NCT05472623","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neo-kan-nct05472623. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Neo-Kan","arms":[{"description":"Arm A treatment: Oral Adagrasib 600 mg twice daily for 6 weeks prior to surgery. Surgical Resection, then standard postoperative therapy(chemo +/- RT).","label":"Arm A","type":"ACTIVE_COMPARATOR"},{"description":"Arm B treatment: Oral Adagrasib 400 mg twice daily for 6 weeks and IV Nivolumab 240mg every 2 weeks for 3 doses prior to surgery. Surgical Resection, then standard postoperative therapy(chemo +/- RT).","label":"Arm B","type":"ACTIVE_COMPARATOR"}],"collaborators":["Mirati Therapeutics Inc.","Bristol-Myers Squibb"],"completion_date":{"date":"2025-09-01","type":"ACTUAL"},"conditions":["Resectable Non-Small Cell Lung Cancer"],"enrollment":{"count":0,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Adagrasib","otherNames":[],"type":"DRUG"},{"name":"Adagrasib/Nivolumab","otherNames":[],"type":"COMBINATION_PRODUCT"}],"last_update":"2025-09-15","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","official_title":"Phase 2 Trial of Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab in Resectable Non-Small Cell Lung Cancer (Neo-KAN)","overall_status":"WITHDRAWN","phases":["PHASE2"],"primary_completion_date":{"date":"2025-06-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Pathologic complete response (pCR) rate","timeFrame":"Within 90 days of surgery"}],"references":[{"citation":"Luo J, Florez N, Donnelly A, Lou Y, Lu K, Ma PC, Spira AI, Ryan D, Husain H. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review. JCO Precis Oncol. 2024 Apr;8:e2300644. doi: 10.1200/PO.23.00644.","pmid":"38579193","type":"DERIVED"}],"start_date":{"date":"2023-03-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab","url":"https://clinicaltrials.gov/study/NCT05472623"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neo-kan-nct05472623"}